MedTrace Logo

PROMES: A Clinical Study in Which Researchers Want to Learn More About the Safety Profile of MESIGYNA (Norethisterone Enantate 50 mg and Estradiol Valerate 5 mg) Used as a Medication to Prevent Pregnancy for Adult Women in Reproductive Age in the Peruvian Population at the Outpatient Clinic.

NCT03901131 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 296

Last updated 2022-12-21

No results posted yet for this study

Summary

Clinical study in which researchers want to learn more about the safety profile of MESIGYNA used as a medication in routine clinical practice to prevent pregnancy. In order to find this out researchers will collect historic and treatment related data during initial visit and follow-up visits of adult women in reproductive age in the Peruvian population at the outpatient clinic. Mesigyna is a combined injectable birth control medication (norethindrone ethanate (50 mg) and estradiol valerate (5 mg)) for women given monthly.

Conditions

  • Contraceptive

Interventions

DRUG

Norethisterone enantate/estradiol valerate (Mesigyna, BAY98-7040)

Follow clinical administration

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-26
Primary Completion
2021-08-31
Completion
2022-02-17

Countries

  • Peru

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03901131 on ClinicalTrials.gov